GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inventiva SA (NAS:IVA) » Definitions » Short Percentage of Float

IVA (Inventiva) Short Percentage of Float


View and export this data going back to 2020. Start your Free Trial

What is Inventiva Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Inventiva's Short Percentage of Float

For the Biotechnology subindustry, Inventiva's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inventiva's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inventiva's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Inventiva's Short Percentage of Float falls into.


;
;

Inventiva Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inventiva SA (NAS:IVA) » Definitions » Short Percentage of Float
Comparable Companies
XPAR:ALCLS XPAR:IPH XPAR:OSE XPAR:NANO XPAR:ALSEN XPAR:GNFT XPAR:DBV XPAR:TNG XPAR:MAAT XPAR:ADOC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
0RNK:UK IVA:France
Address
50 rue de Dijon, Daix, FRA, 21121
Website
https://www.inventivapharma.com
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.